Table 2 Scores of the thirty one statements written in the leaflets inserted in the local and imported NSAIDs
Local Companies | ||||||||
|---|---|---|---|---|---|---|---|---|
No. | Criteria | A (N = 7) | B (N = 5) | C (N = 5) | D (N = 1) | Total scores of Local products (N = 18) | Total scores of Imported products (N = 17) | Total (N = 35) |
1. | Brand name | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
2. | Active ingredient | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
3. | Inactive ingredients (excipients) | 0 | 0 | 0 | 0 | 0 (0) | 17 (100) | 17 (49) |
4. | Therapeutic class | 4 | 4 | 5 | 1 | 14 (78) | 17 (100) | 31 (89) |
5. | Mechanism of action | 0 | 1 | 2 | 0 | 3 (17) | 3 (18) | 6 (17) |
6. | Indications | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
7. | Drug dose | 5 | 3 | 4 | 1 | 13 (72) | 14 (82) | 27 (77) |
8. | Duration of using | 2 | 0 | 2 | 1 | 5 (28) | 12 (71) | 17 (49) |
9. | Missing dose | 7 | 4 | 1 | 1 | 13 (72) | 11 (65) | 24 (69) |
10. | Maximum dose | 5 | 2 | 5 | 1 | 13 (72) | 14 (82) | 27 (77) |
11. | Directions for use | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
12. | Overdose and management | 7 | 4 | 5 | 1 | 17 (94) | 17 (100) | 34 (97) |
13. | Warning and precautions | 7 | 4 | 5 | 1 | 17 (94) | 17 (100) | 34 (97) |
14. | Effect on ability to drive and use machines | 4 | 3 | 2 | 0 | 9 (50) | 16 (94) | 25 (71) |
15. | Contraindications | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
16. | Adverse drug reactions | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
17. | Drug-drug interactions | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
18. | Drug-food interactions | 2 | 3 | 0 | 0 | 5 (28) | 13 (76) | 18 (51) |
19. | Pregnancy considerations | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
20. | Lactation considerations | 7 | 4 | 5 | 1 | 17 (94) | 17 (100) | 34 (97) |
21. | Pediatric considerations | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
22. | Geriatric considerations | 2 | 0 | 1 | 0 | 3 (17) | 15 (88) | 18 (51) |
23. | Possibility of tablet splitting | 0 | 1 | 0 | 0 | 1 (6) | 11 (65) | 12 (34) |
24. | Possibility of crushing and mixing with food or beverages | 7 | 2 | 1 | 1 | 11 (61) | 15 (88) | 26 (74) |
25. | Instructions to convert tablets or capsules into liquid forms | 0 | 0 | 0 | 0 | 0 (0) | 1 (6) | 1 (3) |
26. | Pharmacokinetic information | 0 | 0 | 0 | 0 | 0 (0) | 2 (12) | 2 (6) |
27. | Shelf life | 7 | 5 | 5 | 1 | 18 (100) | 16 (94) | 34 (97) |
28. | Storage | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
29. | Name and address of manufacturers/distributors | 7 | 5 | 5 | 1 | 18 (100) | 17 (100) | 35 (100) |
30. | Date of last revision | 0 | 0 | 0 | 0 | 0 (0) | 13 (76) | 13 (37) |
31. | References | 7 | 2 | 0 | 0 | 9 (50) | 0 (0) | 9 (26) |